Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation
Galderma announces that the U.S. Food and Drug Administration (FDA) has...
Read MoreGalderma announces that the U.S. Food and Drug Administration (FDA) has...
Read MoreGalderma have unveiled results from an innovative open-label post-marketing study which assessed...
Read MoreNow indicated for Correction of Age Related Volume Loss in the Cheek Area. Galderma, a global healthcare company focused on skin health, announced today that it has received US Food...
Read MoreDrs Heidi Waldorf and Doris Day discuss the dermal filler market in the US: what is currently available, what we are likely to see in the next 5 years, and the properties of a hypothetically ‘ideal’ filler.
Read MoreThe increasing availability of black market products is reshaping the practice of injectable treatments. Wendy Lewis investigates how practitioners and industry are fighting back
Read MoreRestylane® stands for innovation as the original non-animal HA dermal filler. With over 20 million treatments worldwide, Galderma are now injecting even more innovation: new delivery systems for Restylane and Restylane Skinboosters™
Read MoreThe lips are a central focus of the face, and particularly affected by the signs of ageing owing to their thin skin. Emmanuelle Bassmann reports on the techniques some physicians are using for their rejuvenation
Read MoreGalderma will unveil two new syringe delivery systems for their comprehensive Restylane® product range designed to meet the changing needs of today’s clinicians at the 12th AMWC 2014, 3–5 April....
Read More